Bexion Pharmaceuticals Experiences Robust Enrollment of Phase I Part 3 First-In-Human Trial Using BXQ-350 for the Treatment of Cancer
COVINGTON, Ky., March 5, 2019 /PRNewswire/ -- Bexion Pharmaceuticals, Inc. (Bexion) announced today Part 3 of their Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer has exceeded expectations in screening and enrollment at their 4 trial sites. In the first few weeks of opening Part 3, over 20 GI and other solid tumor patients enrolled with additional patients in screening. The purpose of Part 3 is to explore safety, and additional indications in rare and gastrointestinal tumors. The Phase I Part 1 study showed that BXQ-350 was well tolerated at all five doses tested with no dose limiting toxicities observed and with no serious adverse events attributed to the therapy. Part 2 tested the highest dose in an additional 36 solid tumor patients. Preliminary data support a safe and tolerable drug profile. "The safety profile of our drug illustrated in Phase I Part 1 and 2 of our trial has created enthusiasm about BXQ-350 among our Principal Investigators (PIs)," stated Dr. Ray Takigiku, Founder and CEO of Bexion. "The objective of Part 3 is to build and expand on the impressive results observed in our prior Phase 1 studies. The rapid enrollment is a reflection of the strong safety profile demonstrated for BXQ-350 and underscores the unmet medical need for new and novel treatment options in these patient populations." About Bexion Pharmaceuticals For more information, visit www.bexionpharma.com. Media Contact: Margaret van Gilse ● 859.757.1652 ● mvangilse@bexionpharma.com. Forward-Looking Statements View original content to download multimedia:http://www.prnewswire.com/news-releases/bexion-pharmaceuticals-experiences-robust-enrollment-of-phase-i-part-3-first-in-human-trial-using-bxq-350-for-the-treatment-of-cancer-300806788.html SOURCE Bexion Pharmaceuticals, Inc. |